Roivant (ROIV) and Priovant Therapeutics reported positive results from the Phase 2 study evaluating brepocitinib in non-anterior non-infectious uveitis, showing the strongest efficacy data in NIU observed to date. In NEPTUNE Study, 29% of subjects receiving brepocitinib 45 mg and 44% of subjects receiving brepocitinib 15 mg met the pre-specified primary efficacy endpoint of treatment failure at week 24. All secondary efficacy endpoints were also positive and dose responsive. Priovant plans to initiate a Phase 3 program in NIU in the second half of calendar year 2024.
Roivant's board has authorized a common share repurchase program, allowing for repurchases of Roivant common shares in an aggregate amount of up to $1.5 billion. Pursuant to the program, on April 2, Roivant entered into a share repurchase agreement with Sumitomo Pharma to repurchase all 71,251,083 common shares held by Sumitomo Pharma at a purchase price per share of $9.10, for an aggregate purchase price of approximately $648.4 million. The transaction with Sumitomo Pharma will reduce Roivant's shares outstanding as of February 9, 2024 by approximately 9%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.